Demo Sign up Log In

Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

Cost of Revenue

$187.00K

Quarterly · Period ending: Jun 30, 2026 · USD

LCTX Cost of Revenue

Latest reported$187.00Kperiod endingJun 30, 2026

Latest reported$187.00Kperiod endingJun 30, 2026

LCTX Quarterly Cost of Revenue ($100.00K → $187.00K)

Quarterly cost of revenue

High-resolution chart · PNG

LCTX cost of revenue history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock Cost of Revenue — Quarterly (USD)
Period ending	Cost of Revenue (USD)
Jun 30, 2001	0
Mar 31, 2001	0
Dec 31, 2000	-19,328
Sep 30, 2000	-19,347
Jun 30, 2000	-18,529
Mar 31, 2000	-18,254
Dec 31, 1999	0
Sep 30, 1999	0
Jun 30, 1999	0
Mar 31, 1999	0
Sep 30, 1998	0
Jun 30, 1998	0
Mar 31, 1998	0
Dec 31, 1997	0
Sep 30, 1997	0
Jun 30, 1997	0
Mar 31, 1997	0
Dec 31, 1996	0
Sep 30, 1996	0
Jun 30, 1996	0
Mar 31, 1996	0
Dec 31, 1995	0
Sep 30, 1995	200,000
Jun 30, 1995	0
Mar 31, 1995	0
Dec 31, 1994	0
Sep 30, 1994	0
Jun 30, 1994	0
Mar 31, 1994	0
Dec 31, 1993	200,000
Sep 30, 1993	200,000
Jun 30, 1993	200,000
Mar 31, 1993	100,000
Dec 31, 1992	200,000
Sep 30, 1992	100,000
Jun 30, 1992	200,000
Mar 31, 1992	100,000

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.